D-dimer
Conditions
Brief summary
This observational study aims to investigate the association between elevated plasma D-dimer levels and the inflammatory response, as well as its impact on survival in adult patients with community-acquired pneumonia. the study participants will be subjected to sampling for D-dimer and calculation of CURB-65 score. this aims to find the relation between them
Detailed description
Community-acquired pneumonia (CAP) is a common and potentially life-threatening infection that affects millions of individuals worldwide each year. D-dimer is a fibrin degradation product that is elevated in many conditions associated with inflammation and coagulation activation, including pneumonia. This is an observational study including a minimum of 50 patients with CAP Patients who will be admitted to the Chest department, or coming to the outpatient clinic at Ain-Shams University Hospitals with CAP, and have the following inclusions: 1. age ≥18 years 2. diagnosis of CAP based on clinical symptoms, laboratory findings, and radiological evidence. 3. Did not have any clinical or radiological signs suggesting COVID-19 pneumonia Exclusion criteria Patients with a history of coagulation disorders, cancer, or other chronic diseases, or refusal to participate. All patients will be subjected to the following: - 1. Full medical history, demographics 2. Thorough clinical examination. 3. laboratory values (including white blood cell count, CRP, and D-dimer), With pre and post sample known precautions (8). 4. Radiological findings (CXR). 5. Severity of illness (based on the CURB-65 score).
Interventions
blood sample for D-dimer
Sponsors
Study design
Eligibility
Inclusion criteria
* Patients who will be admitted to the Chest department, or coming to the outpatient clinic at Ain-Shams University Hospitals with CAP, and have the following inclusions: 1. age ≥18 years 2. diagnosis of CAP based on clinical symptoms, laboratory findings, and radiological evidence.
Exclusion criteria
* Patients with a history of coagulation disorders, cancer, or other chronic diseases, or refusal to participate. * patients who have any clinical or radiological signs suggesting COVID-19 pneumonia.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| find the correlation between plasma D-dimer level and the severity of CAP | in 6 months | measuring D-dimer level (\< 500 µg/L consider negative) on admission and correlating this with CAP severity. |
Countries
Egypt